CNX Therapeutics has acquired four cancer support brands from Clinigen to enhance and diversify its portfolio with cancer support products.
| Acquirer | CNX Therapeutics (US) |
|---|---|
| Target | Clinigen (four cancer support brands) |
| Deal value | Undisclosed |
| Type | Acquisition |
| Close date | Not disclosed |
| Announcement date | Not disclosed |
| Buy-side financial advisors | Not disclosed |
| Sell-side financial advisors | Not disclosed |
| Buy-side legal advisors | Not disclosed |
| Sell-side legal advisors | Not disclosed |
CNX Therapeutics, a healthcare services provider focused on the supply of essential medicines for central nervous system disorders and hospital treatments, has expanded its product portfolio by acquiring four cancer support brands from Clinigen. The acquisition aims to enhance CNX's diversification strategy and provide new in-region direct capabilities.
Strategic Rationale
CNX Therapeutics' expansion into the cancer support market is a strategic move to broaden its offerings beyond central nervous system (CNS) disorders, aligning with its long-term plan to build a partner of choice for commercializing prescription products in Europe. The acquisition of these brands will help CNX diversify its revenue streams and reduce concentration risk, making it more attractive to lenders.
Financial Context
CNX Therapeutics has seen significant growth since its carve-out from Sunovion Pharmaceuticals Europe Limited three years ago, with revenues quadrupling. The company's ability to secure a favorable acquisition facility from Ares in 2023 underscores its improved financial standing and access to capital for future growth.
Advisors
The transaction was facilitated without disclosed financial or legal advisors on either side, reflecting the evolving nature of M&A transactions in the healthcare sector where direct negotiations may be preferred. Inflexion has supported CNX Therapeutics throughout its journey and continues to provide strategic advice.
Outlook
CNX Therapeutics remains committed to its goal of quadrupling revenues again over the next three years through a combination of organic growth, such as in-licensing specialist products, and further acquisitions. With an increasing brand recognition within the healthcare ecosystem, CNX is well-positioned to continue expanding its presence in Western Europe.